Current stock page

Financial Data

RLAY Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

RLAYRelay Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$18.09+$0.01 (+0.06%)

Latest quote

  • Momentum
    76
  • Value
    37
  • Quality
    47
  • Risk resilience
    52
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$350K$3M$7M$0$677K$7.68M$0
Gross Profit$0$350K$2.5M$6.4M-$67.89M-$60.8M$7.68M-$64.43M
Operating Income-$90.25M-$90.82M-$78.59M-$60.63M-$80.39M-$76.85M-$84.87M-$84.98M
Net Income-$81.75M-$83.71M-$73.29M-$54.89M-$74.15M-$70.38M-$77.07M-$76M
EPS-$0.37-$0.41-$0.41-$0.32-$0.43-$0.41-$0.46-$0.45
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$63.93M-$54.11M-$51.11M-$44.87M-$62.12M-$55.26M-$73.21M-$57.87M
Capital Expenditure$0$0$0-$1K$1K-$26K-$384K$0
Free Cash Flow-$63.93M-$54.11M-$51.11M-$44.87M-$62.12M-$55.29M-$73.59M-$57.87M
Net Cash Provided By Operating Activities-$63.93M-$54.11M-$51.11M-$44.87M-$62.12M-$55.26M-$73.21M-$57.87M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$901.69M$967.46M$699.61M$621.33M$670M$728.84M$799.36M$871.3M
Total Debt$27.03M$30.66M$31.57M$32.46M$33.33M$34.18M$47.16M$48.5M
Cash And Cash Equivalents$124.18M$121.19M$204.59M$84.02M$91.56M$113.94M$93.54M$124.29M
Total Liabilities$82.7M$77.45M$57.43M$54.27M$62.29M$63.18M$78.28M$93.5M
Total Stockholders Equity$819M$890.01M$642.18M$567.06M$607.71M$665.66M$721.08M$777.79M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio4.554.53.642.771.850.90.780.81
P/S ratio383.05———————
Debt To Equity0.030.030.050.060.050.050.070.06
Free Cash Flow Yield-5.74%-5.30%-9.13%-15.01%-22.11%-43.84%-48.52%-40.02%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio4.554.53.642.771.850.90.780.81
P/S ratio383.05———————
Return On Equity-35.85%-32.14%-42.47%-48.76%-48.97%-46.80%-46.23%-43.42%
Debt To Equity0.030.030.050.060.050.050.070.06

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-11.98x
Pb4.84x
EPS Growth Yoy13.95%
Gross Margin89.34%
Operating Margin-3094.59%
ROE-40.25%
ROIC-37.86%
Debt To Equity0.03
FCF Yield-5.35%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$18.09
Volume1.48M
RSI (14)47.92
MACD0.15
MACD signal0.11
MACD histogram0.04
ADX (14)14.31
SMA (50)$18.37
SMA (200)$15.54
ATR (14)$1.17
Historical volatility (annualized)80.34%
Volume (20-day average)2.56M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score52/100
Beta1.66
Annual volatility65.80%
Max Drawdown-28.15%
Sharpe Ratio1.84
VaR (95%, 1-day)-5.42%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

RLAY Financial Data FAQ

What is Relay Therapeutics, Inc.'s revenue?

Relay Therapeutics, Inc.'s revenue is one of the core financial data points for RLAY. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Relay Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Relay Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is RLAY's EPS?

RLAY's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Relay Therapeutics, Inc.'s net income?

Relay Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Relay Therapeutics, Inc. generate?

Free cash flow shows how much cash Relay Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Relay Therapeutics, Inc. have?

Cash and debt help frame RLAY's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.